electroCore (ECOR)
(Delayed Data from NSDQ)
$7.02 USD
+0.02 (0.29%)
Updated May 7, 2024 04:00 PM ET
After-Market: $7.34 +0.32 (4.56%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Brokerage Reports
electroCore, Inc. [ECOR]
Reports for Purchase
Showing records 1 - 20 ( 36 total )
Company: electroCore, Inc.
Industry: Medical - Drugs
Strong Revenue Growth Expected to Continue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: electroCore, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: electroCore, Inc.
Industry: Medical - Drugs
Strong 2023 Indicates Start of Inflection; New PT $15.00; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ECOR 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: electroCore, Inc.
Industry: Medical - Drugs
Growth in All Business Segments Bodes Well for 2024; PT Up To $11; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
All Cylinders Firing; New PT $10; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
2023 Strong Start Bodes Well for Full Year; New PT $8; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Guidance Underscores Management Confidence in Strategy; New PT of $7; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Exits 2022 on a Strong Note; New Revenue Streams in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Growth Momentum Maintained in 2Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Starting 2022 on Strong Footing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Teijin Partnership to Pave the Way into Japanese Market; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
Company: electroCore, Inc.
Industry: Medical - Drugs
Strong 2021 Paves Way For Growth in 2022; Adjust PT to $2.75; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: electroCore, Inc.
Industry: Medical - Drugs
GammaCore Commercialization Through UK Online Shop; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S